NEW YORK, April 12, 2017 /PRNewswire/ --
On Tuesday, April 11, 2017, US markets sawa mixed session as 2 sectors closed in green, 4 sectors finished in red, and 3 sectors ended flat for the day. Major US indices were bearish at the close of yesterday's session. The NASDAQ Composite ended the day at 5,866.77, down 0.24%; the Dow Jones
On Tuesday, shares in Waltham, Massachusetts headquartered Tesaro Inc. ended the session 1.93% lower at $141.07 with a total volume of 780,478 shares traded. Tesaro's shares have rallied 204.42% in the past one year. The stock is trading 12.07% above its 200-day moving average. Moreover, shares of the Company, which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the US, have a Relative Strength Index (RSI) of 29.79.
On April 10th, 2017, research firm Janney initiated a 'Neutral' rating on the Company's stock, with a target price of $141 per share. Visit us today and download your complete report on TSRO for free at:
On Tuesday, shares in Cambridge, Massachusetts headquartered Alnylam Pharmaceuticals Inc. recorded a trading volume of 706,856 shares. The stock ended the day 0.81% lower at $48.85. Alnylam Pharma's stock has gained 9.26% in the past three months. The Company's shares are trading above its 50-day moving average by 0.13%. Furthermore, shares of Alnylam Pharma, which discovers, develops, and commercializes novel therapeutics based on RNA interference, have an RSI of 44.26.
On March 30th, 2017, research firm UBS initiated a 'Neutral' rating on the Company's stock, with a target price of $55 per share. The complimentary research report on ALNY can be accessed at:
Norwood, Massachusetts-based Corbus Pharmaceuticals Holdings Inc.'s stock finished Tuesday's session 2.86% lower at $6.80 with a total volume of 818,771 shares traded. Corbus Pharma's shares have rallied 162.55% in the past one year. The Company's shares are trading above its 200-day moving average by 3.47%. Shares of Corbus Pharma, which focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases, have an RSI of 32.25.
On March 30th, 2017, research firm Cantor Fitzgerald reiterated its 'Overweight' rating on the Company's stock with an increase of the target price from $17 a share to $24 a share. Register for free on Stock-Callers.com and download the PDF research report on CRBP at:
Plymouth Meeting, Pennsylvania headquartered Inovio Pharmaceuticals Inc.'s stock edged 0.32% lower, to close the day at $6.15. The stock recorded a trading volume of 579,251 shares. The Company's shares are trading 5.92% and 21.06% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases, have an RSI of 45.57.
On March 16th, 2017, research firm Maxim Group upgraded the Company's stock rating from 'Hold' to 'Buy', with a target price of $10 per share. Get free access to your research report on INO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Cholestatic jaundice occurs when the flow of bile (chole) between the liver and small intestine is ...
Opportunistic infections are microbial infections that can cause disease in persons with a weak ...
The state health insurance programs provide health care support to the below poverty line (BPL) ...View All